Low-dose danazol therapy in idiopathic thrombocytopenic purpura

Yeon Ahn, R. Mylvaganam, R. O. Garcia, C. I. Kim, D. Palow, W. J. Harrington

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Although danazol is effective in the treatment of idiopathic thrombocytopenic purpura, its long-term safety and optimal dosage are not well established. We compared low (50 mg/d) and conventional (400 to 800 mg/d) dosages in 24 patients. Thirteen patients received the low dose 1 to 24 months after conventional doses had been discontinued (group 1). Five patients received low doses immediately after the conventional doses (group 2). Six patients were treated with low doses from the outset (group 3). In group 1, similar responses to either dose were seen in 9 patients, whereas there were better responses to conventional doses in 3 and to the lower dose in 1. All patients in group 2 maintained remissions with low doses. There were two excellent-good responses, one fair, and three poor responses in group 3. Side effects were generally less frequent and severe with the low doses. Low-dose danazol is better tolerated but took longer to obtain remissions, and is useful for maintenance therapy in the management of idiopathic thrombocytopenic purpura.

Original languageEnglish
Pages (from-to)177-181
Number of pages5
JournalAnnals of Internal Medicine
Volume107
Issue number2
StatePublished - Dec 1 1987
Externally publishedYes

Fingerprint

Danazol
Idiopathic Thrombocytopenic Purpura
Therapeutics
Safety

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ahn, Y., Mylvaganam, R., Garcia, R. O., Kim, C. I., Palow, D., & Harrington, W. J. (1987). Low-dose danazol therapy in idiopathic thrombocytopenic purpura. Annals of Internal Medicine, 107(2), 177-181.

Low-dose danazol therapy in idiopathic thrombocytopenic purpura. / Ahn, Yeon; Mylvaganam, R.; Garcia, R. O.; Kim, C. I.; Palow, D.; Harrington, W. J.

In: Annals of Internal Medicine, Vol. 107, No. 2, 01.12.1987, p. 177-181.

Research output: Contribution to journalArticle

Ahn, Y, Mylvaganam, R, Garcia, RO, Kim, CI, Palow, D & Harrington, WJ 1987, 'Low-dose danazol therapy in idiopathic thrombocytopenic purpura', Annals of Internal Medicine, vol. 107, no. 2, pp. 177-181.
Ahn Y, Mylvaganam R, Garcia RO, Kim CI, Palow D, Harrington WJ. Low-dose danazol therapy in idiopathic thrombocytopenic purpura. Annals of Internal Medicine. 1987 Dec 1;107(2):177-181.
Ahn, Yeon ; Mylvaganam, R. ; Garcia, R. O. ; Kim, C. I. ; Palow, D. ; Harrington, W. J. / Low-dose danazol therapy in idiopathic thrombocytopenic purpura. In: Annals of Internal Medicine. 1987 ; Vol. 107, No. 2. pp. 177-181.
@article{d3202468221343dfb9b75119a9ae180e,
title = "Low-dose danazol therapy in idiopathic thrombocytopenic purpura",
abstract = "Although danazol is effective in the treatment of idiopathic thrombocytopenic purpura, its long-term safety and optimal dosage are not well established. We compared low (50 mg/d) and conventional (400 to 800 mg/d) dosages in 24 patients. Thirteen patients received the low dose 1 to 24 months after conventional doses had been discontinued (group 1). Five patients received low doses immediately after the conventional doses (group 2). Six patients were treated with low doses from the outset (group 3). In group 1, similar responses to either dose were seen in 9 patients, whereas there were better responses to conventional doses in 3 and to the lower dose in 1. All patients in group 2 maintained remissions with low doses. There were two excellent-good responses, one fair, and three poor responses in group 3. Side effects were generally less frequent and severe with the low doses. Low-dose danazol is better tolerated but took longer to obtain remissions, and is useful for maintenance therapy in the management of idiopathic thrombocytopenic purpura.",
author = "Yeon Ahn and R. Mylvaganam and Garcia, {R. O.} and Kim, {C. I.} and D. Palow and Harrington, {W. J.}",
year = "1987",
month = "12",
day = "1",
language = "English",
volume = "107",
pages = "177--181",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "2",

}

TY - JOUR

T1 - Low-dose danazol therapy in idiopathic thrombocytopenic purpura

AU - Ahn, Yeon

AU - Mylvaganam, R.

AU - Garcia, R. O.

AU - Kim, C. I.

AU - Palow, D.

AU - Harrington, W. J.

PY - 1987/12/1

Y1 - 1987/12/1

N2 - Although danazol is effective in the treatment of idiopathic thrombocytopenic purpura, its long-term safety and optimal dosage are not well established. We compared low (50 mg/d) and conventional (400 to 800 mg/d) dosages in 24 patients. Thirteen patients received the low dose 1 to 24 months after conventional doses had been discontinued (group 1). Five patients received low doses immediately after the conventional doses (group 2). Six patients were treated with low doses from the outset (group 3). In group 1, similar responses to either dose were seen in 9 patients, whereas there were better responses to conventional doses in 3 and to the lower dose in 1. All patients in group 2 maintained remissions with low doses. There were two excellent-good responses, one fair, and three poor responses in group 3. Side effects were generally less frequent and severe with the low doses. Low-dose danazol is better tolerated but took longer to obtain remissions, and is useful for maintenance therapy in the management of idiopathic thrombocytopenic purpura.

AB - Although danazol is effective in the treatment of idiopathic thrombocytopenic purpura, its long-term safety and optimal dosage are not well established. We compared low (50 mg/d) and conventional (400 to 800 mg/d) dosages in 24 patients. Thirteen patients received the low dose 1 to 24 months after conventional doses had been discontinued (group 1). Five patients received low doses immediately after the conventional doses (group 2). Six patients were treated with low doses from the outset (group 3). In group 1, similar responses to either dose were seen in 9 patients, whereas there were better responses to conventional doses in 3 and to the lower dose in 1. All patients in group 2 maintained remissions with low doses. There were two excellent-good responses, one fair, and three poor responses in group 3. Side effects were generally less frequent and severe with the low doses. Low-dose danazol is better tolerated but took longer to obtain remissions, and is useful for maintenance therapy in the management of idiopathic thrombocytopenic purpura.

UR - http://www.scopus.com/inward/record.url?scp=0023615310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023615310&partnerID=8YFLogxK

M3 - Article

C2 - 3605896

AN - SCOPUS:0023615310

VL - 107

SP - 177

EP - 181

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 2

ER -